AFFILIN
Live / Registered — Registered — Section 71 accepted (as of 02 Feb 2026)
What this means for you
Registered since 27 Oct 2015. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79155885
- Registration number
- 4838850
- Mark type
- Stylized text
- Filed
- 29 Jul 2014
- Published for opposition
- 11 Aug 2015
- Registered
- 27 Oct 2015
- Attorney of record
- Miki Motohashi Iino
Goods and services
- Class 001 — Chemicals: [Chemicals used in industry and science, in particular comprising antibody-like proteins or artificial proteins, except finishing agents for the preparation of synthetic and natural fibres; polypeptides and proteins for industrial purposes, including the manufacturing and purification of proteins, polypeptides, chemicals and other substances; diagnostic and analytic preparations for scientific or research use, not for medical or veterinary use; chemical reagents for analysis in laboratories, not for medical or veterinary use; biological tissue cultures for laboratories, not for medical or veterinary use; biological tissue cultures for laboratory analysis and diagnostics other than for medical or veterinary purposes]
- Class 005 — Pharmaceuticals: [Pharmaceutical and veterinary preparations for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; medical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis; biochemical therapeutic agents for use in the treatment of cystic fibrosis, psychosomatic diseases, depression, epilepsy, endocrinologic disorders, cirrhoses, diseases associated with hormonal disturbances, autoimmune diseases, eye diseases, obesity, metabolic diseases, stroke, infectious diseases, cancer, degenerative diseases, neurodegenerative diseases, asthmatic diseases, dermatologic diseases, musculoskeletal diseases, periodontosis, dental diseases, diabetes, cardiovascular diseases, inflammatory diseases, hematologic diseases, urologic diseases or erectile dysfunctions, psychological diseases, broncholytic diseases, pulmonary diseases, dermatological diseases, lipid metabolism disorders, migraine, dementia, rheumatic disorders, gastric and intestinal diseases, enzyme deficiency and transport proteins disorders, analeptic diseases, anoretic diseases, blood diseases, allergic diseases, anemic diseases, geriatric diseases, cold and flu, hepatic diseases, immunological diseases, cardiac diseases, skeletal and muscle diseases, osteoporosis, ontological diseases, mouth and pharyngeal diseases, asthmatic diseases, bile-duct disorders, and arteriosclerosis, except preparations containing theophylline; diagnostic and analytical preparations for medical and veterinary use; biological and chemical diagnostic reagents for medical use]
- Class 042 — Scientific and technological services: Scientific and industrial research in particular in the biological, biochemical, diagnostic and pharmaceutical fields; biochemistry and pharmaceutical laboratory services; scientific and technological services, namely, scientific research, analysis, testing, in particular in the biological, biochemical, diagnostic and pharmaceutical fields; industrial research and analysis, namely, services in development of biological, biochemical, pharmaceutical and diagnostic products; research for the identification and further development of biological, biochemical, pharmaceutical and diagnostic products
Owner
- Scil Proteins GmbH, Halle, DE
- Scil Proteins GmbH, DE
- Scil Proteins GmbH, DE
Prosecution history
- 02 Feb 2026 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 02 Feb 2026 — REGISTERED-SEC.71 ACCEPTED
- 26 Jan 2026 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 14 Sept 2025 — TEAS SECTION 71 RECEIVED
- 28 Oct 2024 — COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
- 24 May 2024 — INTERNATIONAL REGISTRATION RENEWED
- 30 Apr 2023 — PARTIAL INVALIDATION PROCESSED BY THE IB
- 09 Mar 2023 — PARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
- 09 Mar 2023 — INVALIDATION PROCESSED
- 17 Jan 2023 — PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
- 17 May 2022 — NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
- 17 May 2022 — REGISTERED - PARTIAL SEC 71 ACCEPTED
- 10 May 2022 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 26 Oct 2021 — TEAS SECTION 71 RECEIVED
- 27 Oct 2020 — COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED